Skip to content
  1. Shop all
  2. Monoclonal

M3408-05C-ML650

3,4-Methylenedioxy-N-methylamphetamine, 3,4-Methylenedioxymethamphetamine, MDMA) (MaxLight 650)

Size

£793.00

SKU:
M3408-05C-ML650
Purity:
Purified from mouse ascites.
Storage Conditions:
4°C Do Not Freeze
Supplier:
United States Biological
Host:
Mouse
Immunogen:
Methylenedioxymethamphetamine-BSA (MDMA-BSA).
Clone:
9j15
Format:
Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.
Extra Details:
MaxLight™ 650 is a new Far-IR stable dye conjugate comparable to Alexa Fluor™647, DyLight™649, Cy5™ and offers better labeling efficiency, brighter imaging and increased immunodetection. Absorbance (655nm); Emission (676nm); Extinction Coefficient 250,000. MDMA (3,4-Methylenedioxymethamphetamine, Ecstasy) is a psychoactive amphetamine drug with entactogenic, psychedelic, and stimulant effects. The mechanism of action of MDMA's unusual effects has yet to be fully understood, although it is generally thought that the primary relevant pharmacological characteristic of the drug is its affinity for the plasmalemmal membrane transport protein the serotonin transporter (SERT). The SERT is a part of serotonergic neurons and removes the neurotransmitter serotonin (5-hydroxytryptamine (5-HT)) from the synapse via reuptake for termination and recycling purposes after action potentials. Not only does MDMA inhibit the reuptake of serotonin through its action at the SERT, but it also reverses its action through a process known as phosphorylation. This results in the transporter conversely releasing serotonin into the synapse from inside the cell instead For theSE reasons, MDMA is classified as a combination serotonin reuptake inhibitor (SRI) and serotonin releasing agent (SRA), though it is typically only referred to as the latter definition essentially includes SRI properties. In addition to its actions on serotonin, MDMA causes the same effects on the norepinephrine transporter (NET) and dopamine transporter (DAT), thus inducing release of norepinephrine and dopamine as well, respectively, and hence, it can also be called a norepinephrine-dopamine reuptake inhibitor (NDRI) and norepinephrine-dopamine releasing agent (NDRA), or, in full, as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). MDMA's unusual entactogenic effects have been hypothesized to be, at least partly, the result of indirect oxytocin release via serotonergic neuromodulation. Applications: Suitable for use in FLISA. Other applications not tested. Recommended Dilutions: Optimal dilutions to be determined by the researcher. Affinity Constant: 1x10e10 L/mole Storage and Stability: Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Note: Applications are based on unconjugated antibody.
Shipping Conditions:
Blue Ice